Biotech Tekmira Pharmaceuticals (TKMR) fell more than 10% Friday to a six-month low after an update on its Ebola program induced a loss of investor confidence. Tekmira said that the phase-two trial of TKM-Ebola-Guinea — one of two drugs the firm is working on to treat two strains of the virus — had closed enrollment because “the endpoint indicated that continuing enrollment was not likely to demonstrate an overall therapeutic benefit,” according
Tekmira Pharmaceuticals (TKMR) stock soared on Monday after the Canadian drugmaker said Sunday that it would buy privately held OnCore Biopharma to bolster its efforts to develop a cure for hepatitis B. The merged company has the potential to become a “hepatitis B virus therapeutics powerhouse” that could “create significant value for our shareholders,” said Tekmira CEO Mark Murray in the company’s statement. Tekmira was up more than 43% in midday
Shares of Tekmira Pharmaceuticals and other drugmakers involved in Ebola treatments rose Wednesday after officials disclosed the first case of Ebola initially diagnosed on U.S. soil late Tuesday. Tekmira Pharmaceuticals (TKMR) shares jumped 20.8% to 25.50 by midafternoon trading in the stock market today. In August, Tekmira said that the U.S. Food and Drug Administration had moved its TKM-Ebola drug to a partial clinical hold status from a full